Meloxicam (Mobic) is a nonsteroidal anti-inflammatory compound with analgesic and fever reducer effects. Meloxicam inhibits cyclooxygenase (COX), the enzyme responsible for converting arachidonic acid into prostaglandin H2--the first step in the synthesis of prostaglandins, which are mediators of inflammation. Meloxicam has been shown, especially at its low therapeutic dose, selectively to inhibit COX-2 over COX-1.
| Molecular Weight | 351.4 |
| Formula | C14H13N3O4S2 |
| CAS Number | 71125-38-7 |
| Solubility (25°C) | DMSO 20 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] No authors listed. Am J Health Syst Pharm. Bupivacaine and Meloxicam
[2] Hannah A Blair. Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain
[3] Nasr Y Khalil, et al. Meloxicam
[5] No authors listed. Med Lett Drugs Ther. Qmiiz ODT--an orally disintegrating meloxicam tablet
| Related Immunology/Inflammation Products |
|---|
| Lintuzumab
Lintuzumab is a humanized monoclonal antibody directed against CD33, which is expressed on the majority of myeloblasts in acute myeloid leukemia. |
| Evorpacept
Evorpacept (ALX148) is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region designed to enhance the activity of other anti-neoplastic therapies, with minimal additional toxicity. |
| Litifilimab
Litifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). |
| Belatacept
Belatacept (BMS 224818) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants. |
| MK-4830
MK-4830 is a novel, first-in-class human IgG4 monoclonal antibody targeting the myeloid-specific ILT4 (immunoglobulin-like transcript 4) receptor. MK-4830 catalyzes reprogramming of tumour-associated macrophages, relieving myelosuppression and enhancing T cell function. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
